GlassScriptPhysician profile
Adam D Asarch
NPI 1437380102
$2,383.83
in general payments reported to CMS, 2019-2025
28 companies · $706 in 2025
The $706 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $162 · 2020: $31.71 · 2023: $485 · 2024: $999 · 2025: $706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,190.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $503.35 | 2023-2025 | Skyrizi, Rinvoq |
| Genzyme Corporation | $211.56 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $204.75 | 2019-2025 | Libtayo, Dupixent |
| Novartis Pharmaceuticals Corporation | $172.45 | 2019-2025 | |
| Leo Pharma INC. | $124.73 | 2024-2025 | Adbry |
| Amgen INC. | $118.81 | 2023-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $104.49 | 2023-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $90.54 | 2023-2025 | Ilumya |
| Fresenius Kabi USA, LLC | $88.80 | 2023-2024 | Idacio |
| Janssen Biotech, INC. | $87.81 | 2023-2024 | Tremfya |
| Pfizer INC. | $78.88 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.04 | 2023-2024 | Spevigo |
| Lilly USA, LLC | $70.46 | 2019-2024 | Taltz, Olumiant, Ebglyss |
| Convatec INC. | $53.22 | 2025 | |
| Mimedx Group, INC. | $51.47 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $49.06 | 2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Kyowa Kirin, INC. | $46.08 | 2024 | Poteligeo |
| Arcutis Biotherapeutics, INC. | $42.64 | 2023-2024 | Zoryve |
| Galderma Laboratories, L.P. | $33.59 | 2024 | Oracea |
| Ucb, INC. | $33.21 | 2023-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $28.23 | 2025 | Cabtreo |
| Lnhc, INC | $21.79 | 2025 | Zelsuvmi |
| Allergan, INC. | $19.44 | 2020 | |
| Journey Medical Corporation | $18.24 | 2025 | |
| Organogenesis INC. | $17.27 | 2024 | |
| Helsinn Therapeutics (U.S.), INC. | $13.43 | 2019 | |
| Incyte Corporation | $13.40 | 2024 | Opzelura |
| Dermavant Sciences, INC. | $13.09 | 2023 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Asarch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.